Drug Profile
SPR 741
Alternative Names: SPR 741Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Northern Antibiotics
- Developer Evotec SE; Spero Therapeutics
- Class Antibacterials; Peptides; Polymixins
- Mechanism of Action Cell membrane structure modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Gram-negative infections
Most Recent Events
- 28 Jan 2020 No recent reports of development identified for phase-I development in Gram-negative-infections(In volunteers) in Australia (IV)
- 01 Jan 2020 Spero Therapeutics terminates its licence for SPR 741 worldwide
- 01 Jan 2020 Discontinued - Phase-I for Gram-negative infections (In volunteers) in Australia, United Kingdom (IV)